CTOs on the Move

Vedanta Biosciences

www.vedantabio.com

 
The trillions of microbes that call us home – the human microbiome – perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases. For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious diseases develop. This language is based on a system of signals that our resident microbes use to successfully ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.vedantabio.com
  • 19 Blackstone Street 3rd Floor
    Cambridge, MA USA 02139
  • Phone: 857.706.1427

Executives

Name Title Contact Details

Funding

Vedanta Biosciences raised $50M on 06/07/2016
Vedanta Biosciences raised $27M on 12/24/2018
Vedanta Biosciences raised $18.5M on 05/13/2019
Vedanta Biosciences raised $16.6M on 09/23/2019
Vedanta Biosciences raised $76.9M on 09/30/2020
Vedanta Biosciences raised $25M on 01/12/2021

Similar Companies

Waterdiam

Global Blood Therapeutics

GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.

Syntron Bioresearch

Syntron Bioresearch, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VBI Vaccines

VBI Vaccines Inc.is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology.

Encodia

Encodia is developing an innovative Next-Gen digital proteomics platform to enable democratized protein sequencing. Our goal is to make protein sequencing easy and ubiquitous by using a novel reverse-translation technology that turns peptide sequences into DNA. The DNA can be read by an NGS DNA sequencer, providing a path to breakthrough proteomics research at a scale that is not practical or cost-effective using current technologies.